BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Novartis  Pharma  AG  submitted  on  28  May  2003  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  EMSELEX,  through  the  centralised 
procedure.  After  agreement  by  the  CHMP  on  20  February  2003,  this  medicinal  product  has  been 
referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Prof.  Fernando  de  Andrées-
Trelles 
Co-Rapporteur:  Dr. Pieter Neels 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 23 June 2003 
The Rapporteur's first assessment report was circulated to all CHMP Members on 26 September 
2003. The Co-Rapporteur's first assessment report was circulated to all CHMP Members on 16 
September 2003. 
During  the  meeting  on  21-22  October  2003  the  CHMP  agreed  on  the  consolidated  list  of 
questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the 
company on 23 October 2003. 
The company submitted the responses to the consolidated list of questions on 12 February 2004. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 1 April 2004 
During  the  CHMP  meeting  on  20-22  April  2004,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing and/or in an oral explanation by the applicant. 
The applicant submitted the responses to the List of Outstanding Issues on 7 June 2004. 
During the meeting on  27-29 July 2004, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to EMSELEX on 29 July 2004.  
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 22 October 2004. 
1/1 
EMEA 2004 
 
 
